MX383124B - Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. - Google Patents

Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.

Info

Publication number
MX383124B
MX383124B MX2019002438A MX2019002438A MX383124B MX 383124 B MX383124 B MX 383124B MX 2019002438 A MX2019002438 A MX 2019002438A MX 2019002438 A MX2019002438 A MX 2019002438A MX 383124 B MX383124 B MX 383124B
Authority
MX
Mexico
Prior art keywords
compounds useful
fused tricyclic
pyridazinone compounds
treating
orthomyxovirus infections
Prior art date
Application number
MX2019002438A
Other languages
English (en)
Spanish (es)
Other versions
MX2019002438A (es
Inventor
Aregahegn Yifru
Benjamin R Taft
Daniel Poon
Dennis Christofer Koester
James Clifford Sutton
James R Manning
Lifeng Wan
Qian Zhao
Rama Jain
Vanessa Marx
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019002438A publication Critical patent/MX2019002438A/es
Publication of MX383124B publication Critical patent/MX383124B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2019002438A 2016-08-29 2017-08-25 Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. MX383124B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380712P 2016-08-29 2016-08-29
PCT/IB2017/055137 WO2018042303A1 (en) 2016-08-29 2017-08-25 Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections

Publications (2)

Publication Number Publication Date
MX2019002438A MX2019002438A (es) 2019-07-08
MX383124B true MX383124B (es) 2025-03-13

Family

ID=59923494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002438A MX383124B (es) 2016-08-29 2017-08-25 Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.

Country Status (20)

Country Link
US (4) US10160764B2 (https=)
EP (4) EP3504214B1 (https=)
JP (3) JP7221861B2 (https=)
CN (2) CN113683614B (https=)
AR (1) AR109438A1 (https=)
CA (1) CA3035302A1 (https=)
DK (1) DK4356969T3 (https=)
ES (3) ES3042460T3 (https=)
FI (1) FI4356969T3 (https=)
HR (1) HRP20250885T1 (https=)
HU (1) HUE072776T2 (https=)
JO (1) JOP20170169A1 (https=)
LT (1) LT4356969T (https=)
MX (1) MX383124B (https=)
PL (3) PL3848372T3 (https=)
PT (3) PT3504214T (https=)
SI (3) SI3848372T1 (https=)
TW (3) TWI803467B (https=)
UY (2) UY37378A (https=)
WO (1) WO2018042303A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377396B (es) * 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11247993B2 (en) 2018-01-17 2022-02-15 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
CN118878544A (zh) * 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
CN108440564B (zh) * 2018-04-11 2019-08-06 安帝康(无锡)生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药
US11312727B1 (en) 2018-10-10 2022-04-26 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
WO2021129602A1 (zh) * 2019-12-23 2021-07-01 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022105669A1 (zh) * 2020-11-17 2022-05-27 南京明德新药研发有限公司 含Se大环类化合物
EP4707279A1 (en) * 2023-05-02 2026-03-11 Albius Sciences Beta Pte. Ltd. Substituted tricyclic heterocyclic compound as pharmaceutical for treatment or prevention of covid-19

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2225112A (en) 1938-07-09 1940-12-17 Wright Aeronautical Corp Air cleaner
GB8501542D0 (en) 1985-01-22 1985-02-20 Erba Farmitalia 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives
AUPM354694A0 (en) 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
FR2901795A1 (fr) 2006-05-30 2007-12-07 Fourtillan Snc Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique
CN102203100B (zh) 2008-10-31 2014-08-27 盐野义制药株式会社 具有邻苯二酚基团的头孢菌素
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8927710B2 (en) 2009-06-15 2015-01-06 Shionogi & Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
RU2012131124A (ru) 2009-12-23 2014-01-27 Элан Фармасьютикалз, Инк. Птеридиноны как ингибиторы polo-подобных киназ
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
DK2620436T3 (en) 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
RU2014113230A (ru) * 2011-10-12 2015-11-20 Шионоги Энд Ко., Лтд. Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы
JP6089108B2 (ja) 2012-09-20 2017-03-01 セルトリオン, インク. ドラスタチン10誘導体、その製造方法およびそれを含む抗癌剤組成物
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
US10098913B2 (en) 2013-09-11 2018-10-16 University Of Southern California Composition of stem cells having highly expressed FAS ligand
SI3030549T1 (sl) 2013-09-12 2019-08-30 Janssen Biopharma, Inc. Spojine piridazinona in njihove uporabe
MX377396B (es) 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
US10183945B2 (en) 2016-03-10 2019-01-22 Alios Biopharma, Inc. Method of preparing AZA-pyridone compounds
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP2019059697A (ja) * 2017-09-28 2019-04-18 塩野義製薬株式会社 置換された多環性ピリダジン誘導体およびそのプロドラッグ
US11247993B2 (en) 2018-01-17 2022-02-15 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
CN110041327B (zh) 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN118878544A (zh) 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
JP7282546B2 (ja) 2018-02-28 2023-05-29 日本たばこ産業株式会社 4-メチルジヒドロピリミジノン化合物及びその医薬用途
JP7089596B2 (ja) 2018-02-28 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための7位置換スルホンイミドイルプリノン化合物及び誘導体
PE20210447A1 (es) 2018-02-28 2021-03-08 Japan Tobacco Inc Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico

Also Published As

Publication number Publication date
CN113683614B (zh) 2024-11-08
JP2025081322A (ja) 2025-05-27
PT3504214T (pt) 2021-03-04
LT4356969T (lt) 2025-09-10
US20220041610A1 (en) 2022-02-10
EP3848372A1 (en) 2021-07-14
TW202342482A (zh) 2023-11-01
SI4356969T1 (sl) 2025-10-30
TWI803467B (zh) 2023-06-01
HRP20250885T1 (hr) 2025-09-26
CN109863151B (zh) 2021-09-10
CA3035302A1 (en) 2018-03-08
US10160764B2 (en) 2018-12-25
DK4356969T3 (da) 2025-08-18
EP3504214B1 (en) 2020-12-02
TWI869757B (zh) 2025-01-11
UY37378A (es) 2018-03-23
JOP20170169A1 (ar) 2019-01-30
CN113683614A (zh) 2021-11-23
US20180057501A1 (en) 2018-03-01
MX2019002438A (es) 2019-07-08
TW202517646A (zh) 2025-05-01
ES2974494T3 (es) 2024-06-27
ES3042460T3 (en) 2025-11-20
PL3848372T3 (pl) 2024-04-22
US11912715B2 (en) 2024-02-27
US20250011334A1 (en) 2025-01-09
HUE072776T2 (hu) 2025-12-28
EP4356969A2 (en) 2024-04-24
EP4356969A3 (en) 2024-05-22
AR109438A1 (es) 2018-11-28
ES2859510T3 (es) 2021-10-04
EP4640279A2 (en) 2025-10-29
JP7221861B2 (ja) 2023-02-14
UY40872A (es) 2024-09-13
EP3504214A1 (en) 2019-07-03
PL4356969T3 (pl) 2025-10-20
CN109863151A (zh) 2019-06-07
SI3504214T1 (sl) 2021-04-30
PL3504214T3 (pl) 2021-07-19
EP4640279A3 (en) 2025-12-24
JP2023027102A (ja) 2023-03-01
TW201811800A (zh) 2018-04-01
WO2018042303A1 (en) 2018-03-08
JP2019532033A (ja) 2019-11-07
FI4356969T3 (fi) 2025-08-15
EP4356969B1 (en) 2025-07-09
EP3848372B1 (en) 2023-12-20
PT3848372T (pt) 2024-03-22
US11098051B2 (en) 2021-08-24
US20200123167A1 (en) 2020-04-23
SI3848372T1 (sl) 2024-04-30
PT4356969T (pt) 2025-10-02

Similar Documents

Publication Publication Date Title
MX383124B (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12022550033A1 (en) Compounds useful to treat influenza virus infections
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX388750B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
EA201690372A1 (ru) Азапиридоновые соединения и их применение
PH12017500207B1 (en) Indoles for use in influenza virus infection
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201891644A1 (ru) Антибактериальные соединения и их применение
JO3633B1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
MX376700B (es) Compuestos heterociclicos fusionados como moduladores s1p.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
UA117779C2 (uk) Піразини як модулятори gpr6
CL2017000151A1 (es) Derivados de piridona